Oscotec Ramps Up R&D: What Lies Beyond the Success of Lazertinib?
“It doesn’t end with lazertinib. Keep an eye out for the next candidate in line.”Oscotec is aggressively channeling the revenue secured from the...
Search results for "Phase 3 trial"
Seizure- and Recurrence-Prone Glioma: First New Drug in 20 Years
Being diagnosed with a brain tumor in your 30s or 40s—when you are building your career, raising children, and staying socially active—can upend your...
Daewoong Pharmaceutical Moves to Develop Once-Monthly GLP-1 Obesity Injection
Daewoong Pharmaceutical is teaming up with a biotech startup to develop an obesity treatment administered by injection...
K-Pharma Sets Sights on Veterinary Market: Daewoong Pharmaceutical Leads the Charge
More than 10 South Korean pharmaceutical companies are pivoting toward veterinary medicine as a strategic growth engine.
New Biologic Drug Lands in Korea: Expanded Relief for Chronic Rhinosinusitis and Nasal Polyps
A biologic medication previously recognized for its effectiveness in treating severe asthma is now offering a new...
Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?
A final decision on the approval of RIMQARTO (anbalcabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T)...
Korea’s 40th New Drug ‘Nuviju’ Launches: A Three-Way Battle for the Double-Chin Market
Medytox is set to shake up the aesthetic medicine industry with the launch of "Nuviju," a new treatment for submental...
ABL Bio to Present Two Bispecific Antibody ADC Posters at AACR
ABL Bio announced on the 19th that it will participate in this year’s American Association for Cancer Research Annual...
HK inno.N’s ‘Ecnoglutide’: Can a Late Entrant’s “Hidden Card” Reshape the Obesity Market?
HK inno.N is fast-tracking the South Korean launch of ecnoglutide, a GLP-1 receptor agonist licensed from China’s...
A Single Cancer Shot: Local Injection Triggers Systemic Tumor Disappearance
For decades, one immuno-oncology strategy has held immense promise while repeatedly falling short: the use of CD40...